Prognostic significance of pretreatment systemic immune-inflammation index in patients with prostate cancer: a meta-analysis
Abstract Background The SII (systemic immune-inflammation index) has been extensively reported to have a prognostic value in prostate cancer (PCa), despite the unconformable results. The purpose of this meta-analysis is to quantify the effect of pretreatment SII on survival outcomes in patients with...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-01-01
|
| Series: | World Journal of Surgical Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12957-022-02878-7 |
| _version_ | 1797958639653224448 |
|---|---|
| author | Buwen Zhang Tao Xu |
| author_facet | Buwen Zhang Tao Xu |
| author_sort | Buwen Zhang |
| collection | DOAJ |
| description | Abstract Background The SII (systemic immune-inflammation index) has been extensively reported to have a prognostic value in prostate cancer (PCa), despite the unconformable results. The purpose of this meta-analysis is to quantify the effect of pretreatment SII on survival outcomes in patients with PCa. Methods The following databases were searched: Web of Science, Cochrane Library, PubMed, Embase, and China National Knowledge Infrastructure (CNKI). For exploration of the SII’s correlations with the overall survival (OS) and the progression-free survival/biochemical recurrence-free survival (PFS/bRFS) in PCa, the pooled hazard ratios (HRs) were assessed within 95% confidence intervals (CIs). Results The present meta-analysis covered 10 studies with 8133 patients. Among the PCa population, a high SII was linked significantly to poor OS (HR = 2.63, 95% CI = 1.87–3.70, p < 0.001), and worse PFS/bRFS (HR = 2.49, 95% CI = 1.30–4.77, p = 0.006). However, a high SII was not linked significantly to T stage (OR = 1.69, 95% CI = 0.86–3.33, p = 0.128), the metastasis to lymph node (OR = 1.69, 95% CI = 0.69–4.16, p = 0.251), age (OR = 1.41, 95% CI = 0.88–2.23, p = 0.150), or the Gleason score (OR = 1.32, 95% CI = 0.88–1.96, p = 0.178). Conclusions For the PCa sufferers, the SII might be a promising prognostic biomarker, which is applicable to the high-risk subgroup identification, and provide personalized therapeutic strategies. |
| first_indexed | 2024-04-11T00:21:48Z |
| format | Article |
| id | doaj.art-5cd8845bff864620abd6aaf3b379e112 |
| institution | Directory Open Access Journal |
| issn | 1477-7819 |
| language | English |
| last_indexed | 2024-04-11T00:21:48Z |
| publishDate | 2023-01-01 |
| publisher | BMC |
| record_format | Article |
| series | World Journal of Surgical Oncology |
| spelling | doaj.art-5cd8845bff864620abd6aaf3b379e1122023-01-08T12:13:38ZengBMCWorld Journal of Surgical Oncology1477-78192023-01-0121111310.1186/s12957-022-02878-7Prognostic significance of pretreatment systemic immune-inflammation index in patients with prostate cancer: a meta-analysisBuwen Zhang0Tao Xu1Department of Oncology, Changxing People’s HospitalDepartment of Urology, Changxing People’s HospitalAbstract Background The SII (systemic immune-inflammation index) has been extensively reported to have a prognostic value in prostate cancer (PCa), despite the unconformable results. The purpose of this meta-analysis is to quantify the effect of pretreatment SII on survival outcomes in patients with PCa. Methods The following databases were searched: Web of Science, Cochrane Library, PubMed, Embase, and China National Knowledge Infrastructure (CNKI). For exploration of the SII’s correlations with the overall survival (OS) and the progression-free survival/biochemical recurrence-free survival (PFS/bRFS) in PCa, the pooled hazard ratios (HRs) were assessed within 95% confidence intervals (CIs). Results The present meta-analysis covered 10 studies with 8133 patients. Among the PCa population, a high SII was linked significantly to poor OS (HR = 2.63, 95% CI = 1.87–3.70, p < 0.001), and worse PFS/bRFS (HR = 2.49, 95% CI = 1.30–4.77, p = 0.006). However, a high SII was not linked significantly to T stage (OR = 1.69, 95% CI = 0.86–3.33, p = 0.128), the metastasis to lymph node (OR = 1.69, 95% CI = 0.69–4.16, p = 0.251), age (OR = 1.41, 95% CI = 0.88–2.23, p = 0.150), or the Gleason score (OR = 1.32, 95% CI = 0.88–1.96, p = 0.178). Conclusions For the PCa sufferers, the SII might be a promising prognostic biomarker, which is applicable to the high-risk subgroup identification, and provide personalized therapeutic strategies.https://doi.org/10.1186/s12957-022-02878-7Systemic immune-inflammation indexProstate cancerMeta-analysisPrognostic factorsClinical use |
| spellingShingle | Buwen Zhang Tao Xu Prognostic significance of pretreatment systemic immune-inflammation index in patients with prostate cancer: a meta-analysis World Journal of Surgical Oncology Systemic immune-inflammation index Prostate cancer Meta-analysis Prognostic factors Clinical use |
| title | Prognostic significance of pretreatment systemic immune-inflammation index in patients with prostate cancer: a meta-analysis |
| title_full | Prognostic significance of pretreatment systemic immune-inflammation index in patients with prostate cancer: a meta-analysis |
| title_fullStr | Prognostic significance of pretreatment systemic immune-inflammation index in patients with prostate cancer: a meta-analysis |
| title_full_unstemmed | Prognostic significance of pretreatment systemic immune-inflammation index in patients with prostate cancer: a meta-analysis |
| title_short | Prognostic significance of pretreatment systemic immune-inflammation index in patients with prostate cancer: a meta-analysis |
| title_sort | prognostic significance of pretreatment systemic immune inflammation index in patients with prostate cancer a meta analysis |
| topic | Systemic immune-inflammation index Prostate cancer Meta-analysis Prognostic factors Clinical use |
| url | https://doi.org/10.1186/s12957-022-02878-7 |
| work_keys_str_mv | AT buwenzhang prognosticsignificanceofpretreatmentsystemicimmuneinflammationindexinpatientswithprostatecancerametaanalysis AT taoxu prognosticsignificanceofpretreatmentsystemicimmuneinflammationindexinpatientswithprostatecancerametaanalysis |